Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
This is a short WorldPing brief. The full report was published by Al Jazeera.
Read the full report at Al JazeeraThe combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Brief by WorldPing · Original reporting by CNBC World
WorldPingThe shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
Brief by WorldPing · Original reporting by Fortune
WorldPingThe vaccine reportedly thwarted the cancer's return and spread.
Brief by WorldPing · Original reporting by Ars Technica
WorldPingA new jab extended the length of time patients were cancer free, but it is unclear for how long.
Brief by WorldPing · Original reporting by BBC Health
WorldPingA Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
Brief by WorldPing · Original reporting by Decrypt
WorldPingFor more than a decade, anglers on Lake Memphremagog—which straddles the Quebec–Vermont border—have been catching brown bullhead catfish marked with distinctive black lesions.
Brief by WorldPing · Original reporting by Phys.org
WorldPing